PE20020799A1 - Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco - Google Patents

Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco

Info

Publication number
PE20020799A1
PE20020799A1 PE2002000019A PE2002000019A PE20020799A1 PE 20020799 A1 PE20020799 A1 PE 20020799A1 PE 2002000019 A PE2002000019 A PE 2002000019A PE 2002000019 A PE2002000019 A PE 2002000019A PE 20020799 A1 PE20020799 A1 PE 20020799A1
Authority
PE
Peru
Prior art keywords
drug
polymer
pharmaceutical composition
meylum
methylsulfonil
Prior art date
Application number
PE2002000019A
Other languages
English (en)
Inventor
Ping Gao
Michael J Hageman
Walter Morozowich
Robert Dalga
Kevin Stefanski
Tiehua Huang
Aziz Karim
Fred Hassan
James C Forbes
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20020799A1 publication Critical patent/PE20020799A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL QUE COMPRENDE: a)DE 1% A 75% DE FARMACO POCO HIDROSOLUBLE, CRISTALINO TAL COMO INHIBIDOR DE CICLOOXIGENASA-2 UN COMPUESTO SULFONILFENIL DE FORMULA I, DONDE R3 ES METILO, AMINO, R4 ES H, ALQUILO C1-C4, ALCOXILO; X ES N, CR5; R5 ES H, HALOGENO, Y, Z SON C, N QUE DEFINEN ATOMOS ADYACENTES DE UN ANILLO DE 5-6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON OXO, HALOGENO, METILO, HALOMETILO; O DE 10mg A 400mg DE CELECOXIB, DERACOXIB, VALDECOXIB, ROFECOXIB, ETORICOXIB, 2-(3,5-DIFLUOROFENIL)-3-[4-(METILSULFONIL)FENIL]-2-CICLOPENTEN-1-ONA; ACIDO (S)-6,8-DICLORO-2-(TRIFLUOROMETIL)-2H-1-BENZOPIRAN-3-CARBOXILICO, 2-(3,4-DIFLUOROFENIL)-4-(3-HIDROXI-3-METIL-1-BUTOXI)-5-[4-(METILSULFONIL)FENIL]-3-(2H)-PIRIDAZINONA; b)DISOLVENTE LIQUIDO TAL COMO GLICOLES, ETERES GLICOLICOS CON PESO MOLECULAR DE 100 A 10000; c)POLIMERO REDUCTOR DE TURBIDEZ TAL COMO CARBOXIMETILCELULOSA, METILCELULOSA, DE 15% A 35% DE HIDROXIPROPILMETILCELULOSA; d)VASOMODULADOR EN CANTIDAD SUFICIENTE PARA ALIVIAR EL DOLOR DE CABEZA Y MIGRANA COMO ALQUILXANTINA (CAFEINA, TEOBROMINA, TEOFILINA) CARACTERIZADA PORQUE UNA PARTE (15%) DEL FARMACO ESTA DISUELTO EN EL DISOLVENTE, Y EL POLIMERO INHIBE LA CRISTALIZACION Y/O PRECIPITACION DEL FARMACO EN EL LIQUIDO GASTRICO SIMULADO; LA COMPOSICION LIQUIDA PRESENTA UN RAPIDO INICIO DEL EFECTO TERAPEUTICO Y ES FORMULADA EN CAPSULAS DE GELATINA
PE2002000019A 2001-01-18 2002-01-15 Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco PE20020799A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26255501P 2001-01-18 2001-01-18
US28460801P 2001-04-17 2001-04-17

Publications (1)

Publication Number Publication Date
PE20020799A1 true PE20020799A1 (es) 2002-09-11

Family

ID=26949305

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000019A PE20020799A1 (es) 2001-01-18 2002-01-15 Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco

Country Status (18)

Country Link
US (2) US7115565B2 (es)
EP (1) EP1365812A2 (es)
JP (1) JP2004520359A (es)
KR (1) KR20030070118A (es)
CN (1) CN100335136C (es)
AR (1) AR035735A1 (es)
BR (1) BR0206580A (es)
CA (1) CA2434338A1 (es)
CZ (1) CZ20031844A3 (es)
EA (1) EA006383B1 (es)
HK (1) HK1065959A1 (es)
IL (1) IL156916A0 (es)
MX (1) MXPA03006357A (es)
NO (1) NO20033244L (es)
NZ (1) NZ526976A (es)
PE (1) PE20020799A1 (es)
PL (1) PL363215A1 (es)
WO (1) WO2002056878A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1547474A (zh) * 2001-05-31 2004-11-17 含选择性环加氧酶-2抑制剂及一元醇的可渗透皮肤的组合物
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7078526B2 (en) 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
WO2004061433A1 (en) * 2002-12-30 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
WO2004010972A2 (en) * 2002-07-31 2004-02-05 Pharmacia Corporation Pellicle-resistant gelatin capsule
JP5021934B2 (ja) * 2002-12-30 2012-09-12 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
EP2339328A3 (en) * 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
DE602004014624D1 (de) * 2003-08-29 2008-08-07 Yissum Res Dev Co Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
ES2727577T3 (es) 2004-12-03 2019-10-17 Merck Sharp & Dohme Composición farmacéutica que contiene un agente antinucleante
JP2006265626A (ja) * 2005-03-24 2006-10-05 Dowa Mining Co Ltd 銀回収方法
JP5250258B2 (ja) * 2005-04-20 2013-07-31 中外製薬株式会社 自己乳化型製剤処方の設計方法
DK2433653T3 (da) * 2005-07-15 2019-08-19 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
EP1762232A1 (en) * 2005-09-09 2007-03-14 Warner-Lambert Company LLC Liquid filled delivery system, preferably an HPMC capsule filled with glycerol
AR066076A1 (es) * 2007-04-18 2009-07-22 Sandoz Ag Procedimiento para dosificar sistemas de liberacion de farmacos auto-emulsionantes
NZ581589A (en) * 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
MX2010010214A (es) 2008-03-20 2010-12-21 Virun Inc Derivados de vitamina e y sus usos.
PL2268160T3 (pl) 2008-03-20 2013-05-31 Virun Inc Emulsje zawierające pochodną PEG tokoferolu
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US20110054029A1 (en) * 2009-06-26 2011-03-03 Kuhrts Eric H Water-soluble dietary fatty acids
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
CN103037708B (zh) 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US10874122B2 (en) 2012-02-10 2020-12-29 Virun, Inc. Beverage compositions containing non-polar compounds
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CA2880236C (en) * 2012-07-27 2022-09-13 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
EP2938339B1 (en) * 2012-12-27 2020-08-19 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
MX2015011074A (es) * 2013-02-28 2016-03-09 Pronova Biopharma Norge As Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
WO2015050570A1 (en) 2013-10-06 2015-04-09 Shah Salim Controlled-release formulations comprising torsemide
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
KR20170102223A (ko) * 2014-11-07 2017-09-08 시그모이드 파마 리미티드 사이클로스포린을 포함하는 조성물
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US9901576B2 (en) 2015-11-20 2018-02-27 West-Ward Pharmaceuticals International Limited Stable formulation of phenobarbital sodium injection
US11408900B2 (en) 2016-01-15 2022-08-09 Massachusetts Eye And Ear Infirmary Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
US11911413B2 (en) 2018-02-16 2024-02-27 Proteobioactives Pty Limited Methods and compositions for the treatment of pain and/or inflammation
MX2018013458A (es) * 2018-11-05 2019-07-25 Federico Amezcua Amezcua Composicion farmaceutica que comprende la combinacion de un inhibidor selectivo de la ciclooxigenasa 2 y un carbamato derivado de la guaifenesina para el tratamiento del dolor, inflamacion y contractura muscular.
WO2023220109A1 (en) * 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 pharmaceutical compositions

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU510985B2 (en) 1977-03-29 1980-07-24 Capsugel A.G. Liquid filled capsule
US4498421A (en) 1982-07-19 1985-02-12 Michael Douglas Fredrick Self-cleaning cage
WO1986004501A1 (en) 1985-01-31 1986-08-14 Fujisawa Pharmaceutical Co., Ltd. Soft multi-chamber capsule and method of and apparatus for manufacturing same
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
PT706373E (pt) 1992-03-23 2000-11-30 Univ Georgetown Taxol encapsulado num liposoma e um metodo
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5442252A (en) 1992-11-16 1995-08-15 General Electric Company Lenticulated lens with improved light distribution
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6491938B2 (en) * 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
CN1061036C (zh) * 1993-11-30 2001-01-24 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU2424895A (en) * 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
DE4447770C2 (de) 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
GB9416902D0 (en) 1994-08-20 1994-10-12 Scherer Corp R P Hydrophilic controlled release device
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
ES2139959T3 (es) * 1994-10-27 2000-02-16 Merck Frosst Canada Inc Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
AU4479096A (en) * 1995-01-31 1996-08-21 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5596008A (en) * 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
CA2222138C (en) * 1995-05-25 2008-10-14 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5977103A (en) * 1996-01-11 1999-11-02 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
ES2202492T3 (es) 1996-03-25 2004-04-01 Synthes Ag Chur Pinza regulable para elementos de fijacion para huesos.
GB9607503D0 (en) * 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
ES2311571T3 (es) * 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5741798A (en) * 1996-06-03 1998-04-21 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
KR20000029784A (ko) 1996-08-02 2000-05-25 나까도미 히로다카 경구제제용캡슐과경구캡슐제제
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
WO1998013359A1 (de) 1996-09-24 1998-04-02 Marigen S.A. Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral und antiviral wirksamen estern von baccatin-iii-verbindungen
US5972950A (en) * 1996-10-08 1999-10-26 Laboratories Upsa 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) * 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
DE69725171T2 (de) * 1996-12-10 2004-07-15 G.D. Searle & Co., Chicago Substituierte pyrrolylverbindungen zur behandlung von entzündungen
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
CH688504A5 (de) 1997-03-26 1997-10-31 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamem Taxol und mit Taxol-analogen Verbindungen.
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
JP2002500667A (ja) 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
ATE219363T1 (de) 1997-06-20 2002-07-15 Baker Norton Pharma Lösliche prodrugs von paclitaxel
SI0999826T1 (en) 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr) * 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
CA2329193C (en) * 1998-04-24 2007-01-23 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
WO1999059583A1 (en) * 1998-05-18 1999-11-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
AU757343B2 (en) 1998-09-28 2003-02-20 Capsugel Belgium Nv Enteric and colonic delivery using HPMC capsules
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
AU748996B2 (en) 1998-11-11 2002-06-13 Bioprogress Technology International, Inc. A capsule based drug delivery system
WO2000028976A1 (en) 1998-11-16 2000-05-25 A.B. Technologies, L.L.C. Multi chamber soft capsules and method of making the same
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
JP2000237284A (ja) 1999-02-17 2000-09-05 Shionogi Qualicaps Kk 硬質カプセル製剤
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
ATE312601T1 (de) 1999-05-27 2005-12-15 Acusphere Inc Poröse arzneistoffmatrizen und deren herstellungsverfahren
GB9916033D0 (en) 1999-07-09 1999-09-08 Bioprogress Tech Int Inc A multiple delivery capsule
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition

Also Published As

Publication number Publication date
JP2004520359A (ja) 2004-07-08
KR20030070118A (ko) 2003-08-27
NO20033244D0 (no) 2003-07-17
EP1365812A2 (en) 2003-12-03
CN100335136C (zh) 2007-09-05
IL156916A0 (en) 2004-02-08
EA200300752A1 (ru) 2004-02-26
NO20033244L (no) 2003-09-17
AR035735A1 (es) 2004-07-07
CA2434338A1 (en) 2002-07-25
CN1498114A (zh) 2004-05-19
NZ526976A (en) 2005-02-25
MXPA03006357A (es) 2003-10-06
PL363215A1 (en) 2004-11-15
US20030045563A1 (en) 2003-03-06
BR0206580A (pt) 2003-12-16
HK1065959A1 (en) 2005-03-11
EA006383B1 (ru) 2005-12-29
WO2002056878A3 (en) 2002-12-19
US20020156124A1 (en) 2002-10-24
CZ20031844A3 (cs) 2003-12-17
WO2002056878A2 (en) 2002-07-25
US7115565B2 (en) 2006-10-03

Similar Documents

Publication Publication Date Title
PE20020799A1 (es) Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco
US8686042B2 (en) GSK-3 inhibitors
JP5941598B2 (ja) ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
CA2684105A1 (en) Pyridine derivatives
HRP20171613T1 (hr) Derivati pirazolopirolidina i njihova primjena u liječenju bolesti
CA2571347A1 (en) Piperazine derivatives for the treatment of female sexual disorders
PE20010992A1 (es) Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2
AR069494A1 (es) Derivados de acidos fosfonicos
RU2011102560A (ru) Соединение карбоновой кислоты
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
CA2624621A1 (en) Pyrazine derivatives
EA022420B1 (ru) Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
RU2014107000A (ru) Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств
RU2011119450A (ru) Содержащее конденсированную кольцевую структуру производное и его применение в медицине
US9079876B2 (en) Imidazole derivatives and preparation method and use thereof
Asif Brief overview on recent advances in the development of anti-tubercular compounds containing different heterocyclic ring systems
RU2008106057A (ru) Производные бензимидазола для лечения воспалитнльных заболеваний
RU2466130C2 (ru) Бициклические гетероциклические соединения в качестве ингибиторов fgfr
SI3144306T1 (en) Derivate pyrazine
IL275817B1 (en) Tricyclic compounds, preparations and their medical applications
MX2017011814A (es) Formulacion que incluye complejos supramoleculares estables.
ATE154603T1 (de) Heterozyklische säuren
Vishwasrao Study on bioactive heterocyclic compounds and metal complexes synthesis characterization and biological activities
DK308787A (da) Triazol- og imidazolforbindelser

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed